- Home
- Publications
- Publication Search
- Publication Details
Title
Recent updates on CAR T clinical trials for multiple myeloma
Authors
Keywords
-
Journal
Molecular Cancer
Volume 18, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-11-05
DOI
10.1186/s12943-019-1092-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma
- (2019) Chuang Sun et al. Oncotarget
- Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
- (2019) Yuan He et al. Nature Communications
- Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
- (2019) Juanjuan Zhao et al. Journal of Hematology & Oncology
- A retained transcriptomic profile characterizes CD138+ cells in the short time progression from smoldering to active multiple myeloma.
- (2019) Paola Storti et al. HAEMATOLOGICA
- Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma
- (2019) Reham Ashour et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
- (2019) Adam D. Cohen et al. JOURNAL OF CLINICAL INVESTIGATION
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
- (2019) Jie Xu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
- (2019) Shabnum Patel et al. Frontiers in Oncology
- The potential diagnostic power of CD138+ Microparticles from the plasma analysis for multiple myeloma clinical monitoring
- (2019) Zhao‐Yun Liu et al. HEMATOLOGICAL ONCOLOGY
- How I treat the young patient with multiple myeloma
- (2018) Sara Gandolfi et al. BLOOD
- SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target
- (2018) John Shi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
- (2018) Meletios Dimopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- T Cells Genetically Modified to Express an Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma
- (2018) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel
- (2018) David Porter et al. Journal of Hematology & Oncology
- Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study
- (2018) Meletios Dimopoulos et al. Journal of Hematology & Oncology
- Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
- (2018) Yanyu Pang et al. Molecular Cancer
- Engineering chimeric antigen receptor-T cells for cancer treatment
- (2018) Baixin Ye et al. Molecular Cancer
- Development and Evaluation of an Optimal Human Single-Chain Variable Fragment-Derived BCMA-Targeted CAR T Cell Vector
- (2018) Eric L. Smith et al. MOLECULAR THERAPY
- Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
- (2018) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Chimeric Antigen Receptor Therapy
- (2018) Carl H. June et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- CAR T cell immunotherapy for human cancer
- (2018) Carl H. June et al. SCIENCE
- Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
- (2018) Andrew Spencer et al. HAEMATOLOGICA
- Chimeric antigen receptor T cells targeting the lambda light chain of human immunoglobulin as a viable target for B cell non-Hodgkin lymphoma.
- (2018) Raghuveer Ranganathan JOURNAL OF CLINICAL ONCOLOGY
- Cytokine release syndrome: grading, modeling, and new therapy
- (2018) Delong Liu et al. Journal of Hematology & Oncology
- CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth
- (2018) Robert Berahovich et al. Cancers
- A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
- (2018) Wan-Hong Zhao et al. Journal of Hematology & Oncology
- Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma
- (2018) Jinhuan Xu et al. Journal of Hematology & Oncology
- Universal CARs, universal T cells, and universal CAR T cells
- (2018) Juanjuan Zhao et al. Journal of Hematology & Oncology
- SLAMF7 Is a Critical Negative Regulator of IFN-α–Mediated CXCL10 Production in Chronic HIV Infection
- (2018) Patrick O’Connell et al. JOURNAL OF IMMUNOLOGY
- CD19-directed CAR T cells gain traction
- (2018) Stephen J Schuster LANCET ONCOLOGY
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2018) Stephen J. Schuster et al. NEW ENGLAND JOURNAL OF MEDICINE
- New development in CAR-T cell therapy
- (2017) Zhenguang Wang et al. Journal of Hematology & Oncology
- Cocktail treatment with EGFR-specific and CD133-specific chimeric antigen receptor-modified T cells in a patient with advanced cholangiocarcinoma
- (2017) Kai-chao Feng et al. Journal of Hematology & Oncology
- A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
- (2017) Erhao Zhang et al. Journal of Hematology & Oncology
- A compound chimeric antigen receptor strategy for targeting multiple myeloma
- (2017) K H Chen et al. LEUKEMIA
- CD137–CD137L interaction modulates neointima formation and the phenotype transformation of vascular smooth muscle cells via NFATc1 signaling
- (2017) Wei Zhong et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
- (2017) Sattva S. Neelapu et al. Nature Reviews Clinical Oncology
- Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
- (2017) Sattva S. Neelapu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
- (2017) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- CARs in the Lead Against Multiple Myeloma
- (2017) Maria Ormhøj et al. Current Hematologic Malignancy Reports
- Outcomes of multiple myeloma patients receiving bortezomib, lenalidomide, and carfilzomib
- (2016) Ariana Berenson et al. ANNALS OF HEMATOLOGY
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
- (2016) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents
- (2016) N Majithia et al. LEUKEMIA
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics
- (2015) C. Peters et al. BIOSCIENCE REPORTS
- How I treat high-risk myeloma
- (2015) S. Lonial et al. BLOOD
- Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
- (2015) Alfred L. Garfall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells
- (2014) J. Chu et al. CLINICAL CANCER RESEARCH
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparative analysis of multiple myeloma treatment by CD138 antigen targeting with bismuth-213 and Melphalan chemotherapy
- (2014) S. Gouard et al. NUCLEAR MEDICINE AND BIOLOGY
- Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway
- (2014) R. Abu-Eid et al. Cancer Immunology Research
- Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells
- (2013) T. Tanno et al. BLOOD
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma
- (2012) Y.-T. Tai et al. BLOOD
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
- (2012) Philip L. McCarthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chimeric Antigen Receptor Therapy for B-cell Malignancies
- (2012) David L Porter et al. Journal of Cancer
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- CS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
- (2008) E. D. Hsi et al. CLINICAL CANCER RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started